Table 1.
Characteristics of the study population unadjusted and stratified by race/ethnicity
| Characteristics | NH-White | NH-Black | Hispanic |
|---|---|---|---|
| N | 10341 | 1621 | 2138 |
| Age: mean (SD) | 80 (9) | 75 (9) | 79 (8) |
| Male sex: N (%) | 4722 (46) | 742 (46) | 960 (45) |
| NIHSS: mean (SD) | 7.2 (7.7) | 7.7 (7.8) | 8.1 (7.9) |
| Health insurance: N (%) | |||
| Private | 4664 (45) | 340 (21) | 254 (12) |
| Medicare | 4643 (45) | 1021 (63) | 1266 (59) |
| None | 36 (<1) | 38 (2) | 6 (1) |
| Unknown | 998 (10) | 222 (14) | 602 (28) |
| Arrival by EMS: N (%) | 6270 (61) | 886 (55) | 1230 (58) |
| Current smoker: N (%) | 939 (9) | 173 (11) | 172 (8) |
| Hypertension: N (%) | 6988 (68) | 1188 (73) | 1229 (57) |
| Diabetes: N (%) | 2434 (24) | 635 (39) | 610 (29) |
| Dyslipidemia: N (%) | 4640 (45) | 555 (34) | 685 (32) |
| Atrial fibrillation history: N (%) | 2557 (25) | 175 (11) | 375 (18) |
| CAD/MI: N (%) | 2893 (28) | 289 (18) | 474 (22) |
| Previous stroke/TIA: N (%) | 2666 (26) | 476 (29) | 468 (22) |
| rt-PA, arrive by 2 hrs and treat by 3 hrs: N (%) | 699 (89) | 59 (86) | 145 (91) |
| Early Antithrombotic Use: N (%) | 8305 (96) | 1346 (94) | 1736 (96) |
| Antithrombotics at Discharge: N (%) | 8751 (97) | 1391 (95) | 1785 (95) |
| Anticoagulation for Atrial Fibrillation: N (%) | 1855 (95) | 148 (95) | 297 (94) |
| Smoking cessation counseling: N (%) | 834 (97) | 153 (94) | 153 (96) |
| LDL 100 or ND – Statin: N (%) | 6351 (91) | 1031 (92) | 1332 (93) |
| VTE Prophylaxis: N (%) | 9051 (91) | 1424 (90) | 1867 (90) |
| In-hospital mortality: N (%) | 320 (3) | 62 (4) | 102 (5) |
| 30-day mortality: N (%) | 1193 (12) | 154 (10) | 290 (14) |
| 6-month mortality: N (%) | 2180 (21) | 317 (20) | 500 (23) |
| 1-year mortality: N (%) | 2687 (26) | 396 (24) | 599 (28) |
| 30-day readmission: N (%) | 1445 (15) | 235 (15) | 315 (16) |